Back
to home » Treatment News » Top Stories
 April 30, 2008
|
Improving the Predictive Ability of a Resistance Test
A new method for interpreting the results of the HIV diagnostic company Virco’s predictive phenotype test better predicts actual responses to treatment than an older method, say the authors of a study published in the May 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
April 29, 2008
|
HIV Affects Body Shape and Lipids in Women
HIV-positive women, especially white women, are more likely than HIV-negative women to have belly fat accumulation and changes in cholesterol and triglycerides that indicate an increased risk for heart disease and strokes, say the authors of a study published in the May 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
Interfering with Immune Protein Slows HIV Reproduction
Inhibiting or blocking the production of an immune system-signaling protein made CD4 cells less able to be infected and thus slowed HIV reproduction, according to a press release from the National Institutes of Health’s Human Genome Research Institute (NHGRI).
|
|
|
April 28, 2008
|
Better Antibiotics for Second-Line PCP Treatment
A combination of two oral antibiotics is more effective than the commonly used, yet side effect-prone, intravenous pentamidine for people who’ve failed their first AIDS-related pneumonia regimen, according to the authors of a new study published in the May 1 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS).
|
|
|
April 25, 2008
|
Treatment Failure: Symptoms Matter Too
Symptoms of failing health are nearly as effective as viral loads or CD4 counts in determining if an antiretroviral (ARV) treatment regimen has stopped working and needs to be switched, according to new research published in The Lancet and reported by AIDSmap.
|
|
|
| April 24, 2008
|
April 23, 2008
|
Insulin Resistance Predicts Heart Disease and Stroke Risk
People with insulin resistance—whereby cells become less sensitive to insulin, the hormone that helps control blood sugar—were more likely to have physical symptoms associated with heart disease and stroke risk than people without insulin resistance, according to a study published in the April 23 issue of AIDS.
|
|
|
April 22, 2008
|
African Americans Have Rapid Kidney Disease Progression
African Americans living with HIV and chronic kidney disease (CKD) progress far more rapidly to end-stage renal disease (ESRD)—requiring dialysis or kidney transplantation—than white people with HIV and CKD, according to a study to be published in a future issue of the Journal of Infectious Diseases.
|
|
|
| April 21, 2008
|
April 18, 2008
|
Tropism Predicts CD4 Loss, Not Treatment Response
People who've never taken antiretroviral (ARV) therapy and have detectable strains of HIV that prefer the CXCR4 T-cell receptor face a higher risk of sudden CD4 cell declines than those with CCR5-tropic virus, according to a study published in the May 15 issue of Clinical Infectious Diseases.
|
|
|
April 16, 2008
|
HIV Immunotherapy Shows Promise
Promising data suggesting that an immune-based therapy can be used to reduce levels of HIV in the body have emerged from research using an animal model at the University of Melbourne.
|
|
|
April 15, 2008
|
Vicriviroc Trial Enrolling Treatment First-Timers
Schering-Plough Corporation announced today that it has begun enrolling a phase II study of its experimental CCR5-blocking entry inhibitor vicriviroc for people starting HIV treatment for the first time.
|
|
|
April 14, 2008
|
Tesamorelin for Lipo: More Data Expected
Montreal-based Theratechnologies announced today that the last patient enrolled in its confirmatory Phase III clinical trial of tesamorelin for HIV-associated lipodystrophy has completed 26 weeks of treatment and that results from the study will be released within the next few months.
|
|
|
April 11, 2008
|
Managing Prostate Cancer No Different in HIV
HIV-positive men with prostate cancer appear to respond as well to standard prostate cancer treatment as HIV-negative men do, according to an article to be published in a future issue of BJU International, a British urological journal.
|
|
|
April 10, 2008
|
Most U.K. Patients Start Treatment Without HIV Resistance Info
Nearly two thirds of HIV-positive people starting treatment for the first time in the United Kingdom did so without first finding out if they were infected with a drug-resistant strain of the virus, and one in 10 who did undergo pretreatment testing were found to have at least one mutation known to decrease the sensitivity of the virus to antiretroviral drugs.
|
|
|
April 09, 2008
|
Hetero Men Also at Risk for Anal HPV
Approximately 14 percent of heterosexual men in a Brazilian cohort study were diagnosed with anal lesions likely caused by human papillomavirus (HPV), according to a report published in the March 2008 issue of the International Journal of STD & AIDS.
|
|
|
ADAP Recipients Hit All-Time High in 2007
Earlier this week, the Kaiser Family Foundation and the National Alliance of State and Territorial AIDS Directors (NASTAD) released their 12th annual National ADAP Monitoring Project report outlining changes to state-run AIDS Drug Assistance Programs (ADAP), which help low-income people living with HIV access vital medications.
|
|
|
April 08, 2008
|
Hepatitis B Coinfection Doesn’t Affect HIV Treatment
People with HIV who are coinfected with chronic hepatitis B virus (HBV) respond just as well to antiretroviral (ARV) therapy as people without HBV coinfection, but do have higher death rates, according to a new study published in the May 2008 issue of HIV Medicine.
|
|
|
April 07, 2008
|
Combined Resistance Analysis Better Predicts Treatment Failures
Assessing the combined results of resistance tests for Prezista (darunavir) and Intelence (etravirine) better predicts treatment outcomes than assessing resistance only to the individual drugs, according to a report at NATAP from the 6th European HIV Drug Resistance Workshop in Budapest, Hungary.
|
|
|
Guidelines Panel Leaves Abacavir Recommendations Unchanged
The expert panel that produces the Department of Health and Human Services (DHHS) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents has issued a communication indicating that abacavir (found in Ziagen, Epzicom and Trizivir) should remain a preferred drug for use in people who are starting HIV treatment for the first time.
|
|
|
April 04, 2008
|
High Triglycerides Linked to Fat Abnormalities
High triglycerides are associated with having more fat in the trunk of the body and a loss of fat in the legs of people living with HIV, according to a study to be published in a forthcoming issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
April 03, 2008
|
Bad Teeth Also Bad for Young Men’s Hearts
Gum disease increases the risk of developing heart disease in men under the age of 60, according to a new study published in Circulation: The Journal of the American Heart Association.
|
|
|
April 02, 2008
|
Even Failing Treatment Reduces HIV in the Brain
Despite having similar levels of HIV in the blood, people who continue taking a failing antiretroviral (ARV) regimen have lower levels of HIV and reduced immune activation in the brain compared with people not on treatment, according to a study published in the April 15 issue of the Journal of Acquired Immune Deficiency Syndromes.
|
|
|
April 01, 2008
|
Evolutionary Accident Makes HIV Deadly
HIV may have “accidentally” evolved to become deadly, rather than benign, like similar viruses in monkeys, say researchers at a presentation at the General Microbiology’s 162nd Meeting today in Edinburgh, Scotland.
|
|
|
|
|
|
 |
bigmama41
greensboro
North Carolina
|
justin1o
chicago
Illinois
|
sexyboy3086
orange county
California
|
SpizzleD6977
White Lake
Michigan
|
| Click here to join POZ Personals! |
|
